An understanding of the clinical significance of dapsone-drug interactions is essential for optimal use of this agent. This review aims to provide clinicians with an overview of this topic.
HughesWT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis1998; 27: 191–204.
2.
CooleyLDendleCWolfJet al.Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Int Med J2014; 44: 1350–1366.
3.
BluhmREAdedoyinAMcCarverDGet al.Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther1999; 65: 598–605.
4.
MehtaM. Cimetidine and dapsone-mediated methemoglobinaemia. Anaesthesia2007; 62: 1183–1192.
5.
WinterHRTrapnellCBSlatteryJTet al.The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection. Clin Pharmacol Ther2004; 76: 579–587.
6.
WozelGBlasumC. Dapsone in dermatology and beyond. Arch Dermatol Res2014; 306: 103–124.
7.
AbourayaMSaccoJCHayesKet al.Dapsone-associated methaemoglobinaemia in a patient with slow NPT2*SB haplotype and impaired cytochrome b5 reductase activity. J Clin Pharmacol2012; 52: 272–278.
8.
WinterHRWangYUndadkatJ. CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos2000; 28: 865–868.
9.
GillHTingleMDParkBK. N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of hemotoxicity. Br J Clin Pharmacol1995; 40: 531–538.
10.
Baxter K (ed). Stockley’s drug interactions [online]. London: Pharmaceutical Press, http://www.medicinescomplete.com/ (2015, accessed 1 September 2016).
WallaceKLFilpekRLLa HozRM. Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: case report and review of the literature. J Clin Pharm Therap2016; 41: 441–443.
13.
MatoulkovaPPavekPMalyJ. CYP 450 enzyme regulation by glucocorticoids and consequences in terms of drug interactions. Expert Opin Drug Metab Toxicol2014; 10: 425–435.
14.
ColemanMS. Dapsone: mode of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol1993; 129: 507–513.
15.
ColemanMDRhodesLEScottAKet al.The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br J Clin Pharmacol1992; 34: 244–245.
16.
MoriyamaBHenningSALeungJet al.Adverse interactions between antifungal azoles and vincristine: review and analysis. Mycoses2012; 55: 290–297.
17.
NivoixYLevequeDHerbrechtRet al.The enzymatic basis of drug interactions with triazole antifungals. Clin Pharmacokinet2008; 47: 779–792.
18.
UchaipichatVWinnerLKMackenziePIet al.Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol2006; 61: 427–439.
19.
JacintoPIChandrasekarP. Safety of posaconazole. Expert Opin Drug Saf2013; 12: 265–274.
20.
LewisJAPettyWJHarmonMet al.Hemolytic anemia in two patients with glioblastoma multiforme: a possible interaction between vorinostat and dapsone. J Oncol Pharm Practice2015; 21: 220–223.
21.
VeggiLMPrettoLOchoaEJet al.Dapsone induces oxidative stress and impairs antioxidant defences in rat liver. Life Sci2008; 83: 155–163.
22.
BourcierKHylandRKempshallSet al.Investigation into UDP-glucuronyltransferase (UGT) enzyme kinetics of imidazole- and triazole containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos2010; 38: 923–929.
